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Abstract
Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE inception cohort.
Methods. Patients in the Systemic Lupus International Collaborating Clinics inception cohort (415 months
of SLE diagnosis) were assessed annually for estimated glomerular filtration rate (eGFR), proteinuria and
end-stage renal disease (ESRD). Health-related quality of life was measured by the Short Form (36 ques-
tions) health survey questionnaire (SF-36) subscales, mental and physical component summary scores.
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Results. There were 1827 patients, 89% females, mean (S.D.) age 35.1 (13.3) years. The mean (S.D.) SLE
duration at enrolment was 0.5 (0.3) years and follow-up 4.6 (3.4) years. LN occurred in 700 (38.3%)
patients: 566/700 (80.9%) at enrolment and 134/700 (19.1%) during follow-up. Patients with nephritis
were younger, more frequently men and of African, Asian and Hispanic race/ethnicity. The estimated
overall 10-year incidence of ESRD was 4.3% (95% CI: 2.8%, 5.8%), and with nephritis was 10.1%
(95% CI: 6.6%, 13.6%). Patients with nephritis had a higher risk of death (HR = 2.98, 95% CI: 1.48,
5.99; P= 0.002) and those with eGFR <30 ml/min at diagnosis had lower SF-36 physical component
summary scores (P< 0.01) and lower Physical function, Physical role and Bodily pain scores. Over
time, patients with abnormal eGFR and proteinuria had lower SF-36 mental component summary
(P4 0.02) scores compared to patients with normal values.
Conclusion. LN occurred in 38.3% of SLE patients, frequently as the initial presentation, in a large multi-
ethnic inception cohort. Despite current standard of care, nephritis was associated with ESRD and death,
and renal insufficiency was linked to lower health-related quality of life. Further advances are required for
the optimal treatment of LN.
Key words: systemic lupus erythematosus, lupus, nephritis, inception cohort, outcomes research.
Rheumatology key messages
. Lupus nephritis is associated with a substantial risk of end-stage renal disease and death.
. New treatment strategies are required to improve the outcome of lupus nephritis.
Introduction
Renal disease affects 38% of patients with SLE, with a
range of 1269% [1]. The frequency and severity is
increased in patients with African, Hispanic and Asian an-
cestry [1]. Although a common early manifestation, it can
occur at any time in the disease course [2]. The presen-
tation varies from subclinical laboratory abnormalities to
overt nephritis and nephrotic syndrome. Despite recent
advances, some studies report progression to end-stage
renal disease (ESRD) and mortality has not declined in the
last decade [3, 4].
Improved outcomes of nephritis result from better treat-
ment of both primary pathogenetic mechanisms and sec-
ondary co-morbidities. Administration of i.v. CYC [5, 6]
and oral MMF are effective for induction [79] or mainten-
ance therapy [10, 11]. Open-label studies of targeted B-
cell depletion therapies have been positive [12, 13], al-
though unconfirmed in controlled studies [14]. These
immunomodulatory strategies and treatment of co-
morbidities have been incorporated into recent treatment
guidelines [15, 16]. The value of future treatment strate-
gies will be determined by comparison with current stand-
ard of care.
Between 1999 and 2012 the Systemic Lupus
International Collaborating Clinics (SLICC) established
the SLICC inception cohort for the long-term study of clin-
ical outcomes in SLE. The objective of the current study
was to evaluate the short-term outcomes, as reflected by
health-related quality of life (HRQoL), ESRD and death in
patients with LN receiving standard of care in this interna-
tional multi-ethnic/racial observational cohort of newly
diagnosed SLE patients.
Patients and methods
Research study network
The study was conducted by members of the SLICC net-
work [17]. Data were collected per protocol at enrolment
and annually (±6 months) thereafter and entered into a
centralized database. Each of the participating centre’s
institutional research ethics review boards approved the
SLICC inception cohort study, including this present
analysis.
Patients
Patients fulfilled the ACR classification criteria for SLE
[18] and provided written informed consent for the
SLICC inception cohort. Enrolment occurred up to 15
months following diagnosis. Demographic variables
included age, gender, race/ethnicity and education.
Medication history and lupus-related variables, such as
the SLEDAI-2K [19] and SLICC/ACR damage index (SDI),
were also recorded [20]. Laboratory testing included
haematology, chemistry and immunology required for
SLEDAI-2K and SDI scores. Patient self-reported
HRQoL was measured by the subscale and summary
scores of the Short Form (36 questions) health survey
questionnaire (SF-36) [21].
LN
Nephritis was identified by the renal disorder variable of
the ACR classification criteria [18, 22] and/or biopsy evi-
dence of nephritis as per the International Society of
Nephrology and Renal Pathology Society (ISN/RPS) cri-
teria [23].
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Renal variables and data collection
The SLICC inception cohort was not initially established
for the study of renal disease. Thus, some renal data was
garnered retrospectively by chart review. The ISN/RPS
classification [23] and activity/chronicity scores of Austin
et al. [24] were derived from renal biopsy reports. The
National Kidney Foundation (NKF) classification of chronic
kidney disease (CKD) [25] and estimated glomerular filtra-
tion rate (eGFR) using the Modification of Diet in Renal
Disease equation [26] were determined at each assess-
ment. Estimated proteinuria (ePrU) was measured by
either 24-h urine collection or spot urine total protein:cre-
atinine ratio [27, 28]. ESRD was determined from the SDI
renal variable [29].
At each assessment, patients were assigned to one of
three eGFR and ePrU states. For eGFR: state 1 (eGFR:
>60 ml/min); state 2 (eGFR: 3060 ml/min); and state 3
(eGFR: <30 ml/min). For ePrU: state 1 (ePrU: <0.25 g/day);
state 2 (ePrU: 0.253.0 g/day); and state 3 (ePrU: >3.0 g/
day).
Statistical analyses
Descriptive statistics were used to summarize enrolment
data, and Chi-square tests and t-tests were performed as
appropriate. A simple ordinal regression based on gener-
alized estimating equation (GEE) methods was used to
assess the trends of eGFR and ePrU states as well as
NKF classification of CKD over time after LN diagnosis.
Non-parametric estimates of the cumulative incidence
function for the time until ESRD and death were calculated
using KaplanMeier-like methodology [30]. A Cox regres-
sion with a time-varying covariate was also used to exam-
ine the effect of LN diagnosis on the competing risks of
ESRD and death. Analyses of HRQoL outcomes at enrol-
ment or at diagnosis of LN were based on simple linear
regression models. For analyses of the HRQoL longitu-
dinal outcomes, linear regression models with GEE were
used to take into account the correlation between multiple
observations within patients. Hypothesis tests for the sig-
nificance of regression parameters were performed using
Wald tests (Cox regression) and score tests (GEE ana-
lyses), and 95% CIs were calculated.
Results
Patients
A total of 1827 patients were recruited between October
1999 and December 2012 from SLICC centres in the USA
[n= 528 (28.9%)], Europe [n= 486 (26.6%)], Canada
[n= 421 (23.0%)], Mexico [n= 223 (12.2%)] and Asia
[n= 169 (9.3%)]. Of these, 89% were female, and at enrol-
ment the mean (S.D.) age of the cohort was 35.1 (13.3)
years with a varied racial/ethnic mix, although predomin-
antly Caucasian (Table 1).
At enrolment, the mean (S.D.) disease duration was 0.5
(0.3) years and patients had low SLEDAI-2K and SDI
scores while receiving a range of lupus medications.
Annual assessments varied from 1 to 13, with a mean
follow-up of 4.6 (3.4) years. Eighty patients (4.4%) were
lost to follow-up for reasons that included relocation, living
excessive distance from the clinic, referral to a non-
participating site, voluntary withdrawal and change in in-
surance status.
Onset and characteristics of patients with LN
LN occurred in 700 (38.3%) patients: 566/700 (80.9%) at
the enrolment visit and 134/700 (19.1%) during follow-up
(Fig. 1). Renal biopsies were performed on 395/700
(56.4%) patients, the majority (86.6%) when nephritis
was first suspected; in 377/395 (95.4%) these were of
sufficient quality to identify ISN/RPS classes (%): I: 9
(2.4), II: 36 (9.5), III: 101 (26.8), IV: 163 (43.2), V: 120
(31.8) and VI: 3 (0.8). Twenty-one and 34 biopsies were
class III/V and IV/V, respectively. Of the 101 class III biop-
sies, 72 were active (A), 19 were active and chronic (A/C),
and 10 were chronic (C). Among the 163 class IV biopsies,
additional information was available on 127: 50 were class
IV-S (27 A, 16 A/C and 7 C) and 77 were Class IV-G (50 A,
15 A/C and 12 C). For all of the 377 biopsies, the mean
(S.D.) activity index was 4.3 (3.3) and the mean (S.D.) chron-
icity index was 2.7 (2.6).
There were 547/566 (96.6%) patients with nephritis who
had renal disorder at enrolment. The 19 patients diag-
nosed only by renal biopsy had the following ISN/RPS
class: I: 4 (21.1), II: 2(10.5), III: 6 (31.6), IV: 5 (26.3), V:
5 (26.3) and VI: 0 (0). There were two and one biopsies
with class III/V and IV/V, respectively. Of the 134 patients
who were diagnosed with LN subsequent to the enrolment
visit, there were 128/134 (94.8%) who had renal disorder.
The six patients diagnosed only by renal biopsy had the
following ISN/RSP classes: I: 1, II: 1, III: 1, IV: 3, V: 0 and
VI: 0.
Patients with LN at enrolment were younger and more
frequently men and of African, Asian and Hispanic race/
ethnicity (Table 1). Nephritis patients had a higher fre-
quency of ACR classification criteria [18] for serositis,
neurological disorder and immunological disorder and a
lower frequency of mucocutaneous disease, arthritis and
ANA. The higher mean total SLEDAI-2K in patients with
nephritis was due to the inclusion of renal variables in the
index score. Both the mean total and similarly adjusted
SDI score was higher in patients with LN. Corticosteroids
and immunosuppressive drugs were used more frequently
and antimalarials less frequently (49.1%) in the nephritis
group at enrolment, although antimalarial use increased to
72% over the study. Hypertension was more frequent in
patients with nephritis.
Of the 1827 patients at the enrolment visit, 96 (5.3%)
were ANA negative. There were no statistically significant
differences in ACR classification criteria between ANA-
positive and ANA-negative nephritis patients, with the ex-
ception of a higher frequency of immunological disorder in
the ANA-positive group (88.4% vs 47.5%, P< 0.001).
Twenty-seven (8/40 ANA-negative nephritis group and
19/56 in non-nephritis group) of the 96 patients who
were ANA negative at enrolment became ANA positive
during the study.
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Outcome of LN
Adjusting for gender, age at enrolment and race/ethnicity,
a Cox regression analysis on the competing risks of ESRD
and death, with the diagnosis of LN used to define a time-
dependent covariate, indicated that once patients were
diagnosed with LN, they had higher risks of developing
ESRD [hazard ratio (HR) = 44.7, 95% CI: 6.1, 329.7;
P< 0.001] and death (HR = 3.2, 95% CI: 1.6, 6.5;
P= 0.002).
The estimated cumulative incidence of ESRD (as
defined by the SDI) for the entire cohort at 10 years
following enrolment was 4.3% (95% CI: 2.8%, 5.8%)
(Fig. 2a). For all patients with LN, the cumulative incidence
of ESRD at 10 years after the diagnosis of LN was 10.1%
(95% CI: 6.6%, 13.6%) (Fig. 2b). Excluding patients who
ever developed LN, the estimated cumulative incidence of
ESRD was 0.5% (95% CI: 0%, 1.4%) (Fig. 2c), albeit that
this is an ad hoc analysis because some patients are
excluded on the basis of developing LN following the
enrolment visit.
The estimated cumulative incidence of death from all
causes for the entire cohort at 10 years after enrolment
was 4.4% (95% CI: 2.7%, 6.1%) (Fig. 2a). Patients with LN
at enrolment and those who never developed LN had a
cumulative incidence of death at 10 years of 5.0% (95%
CI: 2.3%, 7.6%) (Fig. 2d) and 3.6% (95% CI: 0.9%, 6.2%)
(Fig. 2d), respectively. In light of the very significant asso-
ciation between time-dependent LN status and death in
the Cox regression, these overlapping confidence inter-
vals are likely due to the limited data available to estimate
cumulative incidences at single time points late in the
follow-up period. An overall test of a difference in these
curves using the log-rank test of no difference is signifi-
cant (P= 0.03). The number of patients at the time points
TABLE 1 Demographic and clinical manifestations of SLE patients with and without LN at enrolment
LN patients Non-LN patients P-value All patients
No. of patients 566 1261 1827
Age, mean (S.D.), years 31.3 (11.9) 36.9 (13.6) <0.001 35.1 (13.3)
Gender, n (%)
Female 477 (84.3) 1149 (91.1) <0.001 1626 (89.0)
Male 89 (15.7) 112 (8.9) 201 (11.0)
Race/ethnicity, n (%)
Caucasian 182 (32.2) 716 (56.9) <0.001 898 (49.2)
Hispanic 138 (24.4) 142 (11.3) 280 (15.4)
Asian 100 (17.7) 172 (13.7) 272 (14.9)
African 121 (21.4) 182 (14.5) 303 (16.6)
Other 24 (4.2) 47 (3.7) 71 (3.9)
Disease duration, mean (S.D.), years 0.5 (0.3) 0.5 (0.4) 0.353 0.5 (0.3)
ACR classification criteria, n (%)
Malar rash 202 (35.7) 463 (36.7) 0.712 665 (36.4)
Discoid rash 48 (8.5) 179 (14.2) <0.001 227 (12.4)
Photosensitivity 140 (24.7) 514 (40.8) <0.001 654 (35.8)
Oral/nasopharyngeal ulcers 178 (31.5) 500 (39.7) <0.001 678 (37.1)
Serositis 179 (31.6) 318 (25.2) 0.005 497 (27.2)
Arthritis 380 (67.1) 989 (78.4) <0.001 1369 (74.9)
Renal disorder 547 (96.6) 0 (0) 547 (29.9)
Neurological disorder 39 (6.9) 49 (3.9) 0.008 88 (4.8)
Haematologic disorder 366 (64.7) 760 (60.3) 0.083 1126 (61.6)
Immunologic disorder 484 (85.5) 912 (72.3) <0.001 1396 (76.4)
ANA 526 (92.9) 1205 (95.6) 0.027 1731 (94.7)
SLEDAI, mean (S.D.) 8.5 (6.7) 4.0 (4.0) <0.001 5.4 (5.4)
SLEDAI without renal, mean 3.6 (3.8) 3.8 (3.7) 0.393 3.7 (3.7)
SDI score, mean (S.D.) 0.5 (0.9) 0.2 (0.6) <0.001 0.3 (0.7)
SDI score without renal, mean (S.D.) 0.4 (0.7) 0.2 (0.6) 0.008 0.3 (0.7)
Medications, n (%)
Corticosteroids 515 (91.6) 750 (60.3) <0.001 1265 (70.0)
Antimalarials 277 (49.1) 954 (76.0) <0.001 1231 (67.6)
Immunosuppressants 397 (70.5) 331 (26.4) <0.001 728 (40.0)
Co-morbidities/lifestyle
Diabetes, n (%) 27 (4.8) 37 (3.0) 0.070 64 (3.5)
Hypertension, n (%) 330 (58.3) 205 (16.3) <0.001 535 (29.3)
Current smoker, n (%) 63 (11.2) 210 (16.7) 0.003 273 (15.0)
Alcohol, mean (S.D.) 0.6 (1.9) 1.2 (3.4) <0.001 1.0 (3.0)
BMI, mean (S.D.) 25.0 (5.9) 25.4 (5.9) 0.129 25.3 (5.9)
Duration of follow-up
Years, mean (S.D.) 5.0 (3.6) 4.5 (3.3) 0.008 4.6 (3.4)
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FIG. 1 Onset of lupus nephritis following enrolment into the SLICC cohort
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FIG. 2 Estimated cumulative incidence of end-stage renal disease and death
End-stage renal disease (all causes) in the total SLICC cohort (A) and in those with (B) and without (C) LN. The estimated
cumulative incidence of death (all causes) for those with LN at enrolment and those who never developed nephritis (D).
ESRD: end stage renal disease.
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for curves in Fig. 2 are provided in a supplementary Table
S1, available at Rheumatology Online. For patients with
LN, the cumulative incidence of death at 10 years follow-
ing the diagnosis of LN was 5.9% (95%CI: 3.3%, 8.4%)
(Fig. 2b). Of the 39 patients who died, only 1 was due to
ESRD. The others were attributed primarily to cardio-
respiratory causes (18), infection (8), neurological disease
(6), malignancy (2) and miscellaneous causes (4).
Additional analyses were performed in which the use of
antimalarials at enrolment was added to the Cox regres-
sion analyses [details are provided in a supplementary
Table S2, available at Rheumatology Online]. Controlling
for gender, age at enrolment, race/ethnicity and the diag-
nosis of LN, antimalarial use at enrolment was not asso-
ciated with the risk of ESRD (HR = 0.888, 95% CI: 0.473,
1.667; P= 0.711), but patients taking antimalarials at
enrolment had longer survival [HR (for death) = 0.34,
95% CI: 0.15, 0.63; P= 0.001]. Controlling for gender,
age at enrolment, antimalarial use at enrolment and at
the diagnosis of LN, Hispanic patients had shorter survival
than other races/ethnicities [HR (for death) = 2.60 (vs
Caucasian), 95% CI: 1.12, 6.03]. We also examined the
effect of ISN/RPS class on ESRD (n= 16) and death (n= 8).
The global tests on the impact of all ISN/RPS classes on
development of ESRD (P= 0.35) and survival (P= 0.37)
were not statistically significant. However, univariate
analyses revealed a statistically significant association
between ISN/RPS Class IV LN (vs other ISN/RPS classes)
and the development of ESRD (HR = 2.99, 95% CI: 1.04,
8.62; P= 0.04).
The number and proportion of patients in each of the
three eGFR and ePrU states and CKD stage at LN diag-
nosis and at the third and fifth annual follow-up assess-
ment after LN diagnosis is summarized in Table 2. There
was no demonstrable change in the distribution of eGFR
states, but there was a markedly lower frequency of ePrU
state 3 over time (P< 0.001). There was no significant
overall change in the proportion of patients with the six
stages of CKD.
LN and HRQoL at enrolment and follow-up
SF-36 subscale and summary scores were not signifi-
cantly lower in patients with LN at enrolment compared
with the enrolment values for patients who never de-
veloped nephritis. However, the subscale scores for
Bodily pain and Vitality scores were lower in non-LN pa-
tients (data not shown). Patients with LN and eGFR state 3
at diagnosis had significantly lower scores in three sub-
scales (Physical function, Role physical and Bodily pain)
(Fig. 3) and in the Physical component summary score of
the SF-36 (P< 0.01). These findings were similar when
adjustment was made for age at SLE diagnosis, gender,
location, race/ethnicity, SLEDAI (without renal variables)
and medication. No adjustment could be made for SDI
TABLE 2 The number (%) of patients in eGFR and ePrU states 13 and in 06 stages of chronic kidney disease at
diagnosis of LN, 3 and 5 years later
Diagnosis 3 years after diagnosis 5 years after diagnosis P-value
eGFR, n (%) 0.443
State 1 (eGFR: >60 ml/min) 583 (86.6) 350 (85.2) 248 (87.6)
State 2 (eGFR: 3060 ml/min 70 (10.4) 44 (10.7) 20 (7.1)
State 3 (eGFR: <30 ml/min) 20 (3.0) 17 (4.1) 15 (5.3)
Total 673 411 283
ePrU, n (%) <0.001
State 1 (ePrU: <0.25 g/day) 252 (39.5) 252 (62.2) 173 (62.2)
State 2 (ePrU: 0.253.0 g/day) 286 (44.8) 134 (33.1) 93 (33.5)
State 3 (ePrU: >3.0 g/day) 100 (15.7) 19 (4.7) 12 (4.3)
Total 638 405 278
NKF classification of CKD, n (%) 0.147
Stage 0 451 (69.2) 301 (74.5) 196 (70.8)
Stage 1 99 (15.2) 36 (8.9) 33 (11.9)
Stage 2 60 (9.2) 34 (8.4) 26 (9.4)
Stage 3 29 (4.5) 20 (5.0) 12 (4.3)
Stage 4 4 (0.6) 4 (1.0) 1 (0.4)
Stage 5 9 (1.4) 9 (2.2) 9 (3.3)
Total 652 404 277
Stage 0: no CKD; Stage 1: kidney damage with normal or increased eGFR (590 ml/min/1.73 m2); Stage 2: kidney damage with
mild decrease in eGFR (6089 ml/min/1.73 m2); Stage 3: moderate decrease in eGFR (3059 ml/min/1.73 m2); Stage 4: severe
decrease in eGFR (1529 ml/min/1.73 m2); Stage 5: kidney failure (<15 ml/min/1.73 m2 or dialysis). The discrepancy between
the number of patients in eGFR states and CKD classification stages is due to methodological differences for making these
determinations: eGFR is measured at a specific time point, whereas CKD classification reflects a persistent abnormality in
eGFR for 53 months and sometimes requires a determination of proteinuria or renal imaging. eGFR: estimated glomerular
filtration rate; ePrU: estimated proteinuria; NKF: National Kidney Foundation; CKD: chronic kidney disease.
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scores due to the short disease duration at enrollment,
which precluded determining an SDI score in many pa-
tients. For ePrU states at the same assessments, the Role
physical scores were lower in ePrU state 3 [28.6 (40.5)]
compared with ePrU state 1 [46.8 (42.7)] and state 2 [42.0
(42.8)] (unadjusted global P= 0.008 and P= 0.08 when ad-
justed for potential confounders).
Adjusting for years after LN diagnosis, there were stat-
istically significant but relatively small declines in SF-36
physical component summary and mental component
summary values for patients in eGFR or ePrU states 2
and 3 over time (Table 3). After adjustment for gender,
age at SLE diagnosis, race/ethnicity, SLEDAI (without
renal variables), medication and SLICC damage score
(without renal variables), all but the relationship between
physical component summary and ePrU states remained
significant (Table 3). There was no statistical evidence for
the dependence of these relationships on time.
Discussion
Since Merrell and Shulman [31] reported a 50% 4-year
survival in the 1950s, renal and overall survival in patients
with LN have steadily improved [32, 33]. This is attributed
to multiple factors, including earlier diagnosis and access
to health care, advances in therapy with immunosuppres-
sion, dialysis and transplantation and treatment of co-
morbidities. However, other studies have suggested that
ESRD and associated mortality have not changed over the
past two decades [3, 4]. The current prospective, obser-
vational study reflects the outcome of LN in a large
international multi-racial/ethnic disease inception cohort
of SLE patients receiving standard of care for up to 12
years. Although the outcomes are generally favourable,
the findings indicate room for further improvement.
The SLICC inception cohort, the largest of its kind, is
well placed to address the objectives of the current study.
The frequency of the initial manifestations of SLE, as re-
flected by individual ACR classification criteria [18], is
comparable with that of another large cohort [34] and in-
dicates a general lupus population without major selection
bias. At presentation, patients had moderate global SLE
disease activity and mild organ damage. The cumulative
frequency of nephritis of 38.3% in our cohort is very simi-
lar to the overall incidence of 37.8% in 2290 SLE patients
enrolled in studies from North America, Europe and the
Middle East [1]. The predilection for nephritis to present
around the time of diagnosis of SLE has also been noted
in another previous large observation study [35]. Other
features such as a higher frequency of nephritis at a
younger age [36, 37], in men [35, 38] and in patients of
non-Caucasian race/ethnicity [3537, 39], and a higher fre-
quency of co-morbidities such as hypertension [40, 41]
provide further evidence for the validity of the cohort
and generalizability of the findings. More frequent use of
corticosteroids and immunosuppressive agents with
nephritis is to be expected and is in line with current treat-
ment guidelines [15, 16].
The outcome of LN has frequently been determined by
total and renal survival, changes in renal function and
achievement of partial or complete remission, albeit vari-
ably defined. In the current study, we also selected the
FIG. 3 Spidergram of SF-36 subscale scores at diagnosis of lupus nephritis in three eGFR states
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hard end-points of total and renal survival, the more fre-
quent and more sensitive outcome of clinically meaningful
defined states for renal function and ePrU, and the asso-
ciation with the less tangible but quantifiable outcome of
HRQoL.
In a European multicentre study of 1000 prevalent SLE
patients [34], 97.1% of whom were white and followed
between 1990 and 2000, the overall 10-year survival
was 92%. In the 279 (27.9%) patients who presented
with nephritis at onset of the study, the 10-year survival
was 88%, compared with 94% in patients without nephro-
pathy. In the current study the estimated 10-year survival
in the entire cohort and in patients with and without neph-
ritis was 95.7, 94.5 and 96%, respectively. Although this
may represent improvement in the outcome of LN, a more
likely explanation is the inherent difference between a
prevalent and an inception cohort. For example, the
mean disease duration at enrolment into the European
[42] and SLICC cohorts was 6 years and 6 months, re-
spectively, and longer disease duration is an independent
risk for mortality. In both studies, death was attributed to
multiple causes and followed ESRD in only 1/40 (2.5%)
patients in our study.
The frequency of ESRD, as defined by haemodialysis or
renal transplantation, in the European multicentre study
[34] between 1990 and 2000 was 37/1000 (3.7%). Two
recent registry and population health studies in the USA
[36, 37], involving 1156 and 2278 prevalent SLE patients
over 3 years (200204), reported an overall frequency of
ESRD of 6.713.3%, depending upon the case definition
TABLE 3 Univariate and multivariate regression analysis for SF-36 summary scores over time following the diagnosis
of LN
MCS PCS
Parameter Estimate (95% CI) P-value Estimate (95% CI) P-value
Univariate regression for eGFR states
Intercept 47.84 (47.06 to 48.62) 43.24 (42.47 to 44.01)
eGFR state 3 0.91 (3.76 to 1.93) 0.019 4.19 (7.09 to 1.28) 0.010
eGFR state 2 2.53 (4.17 to 0.89) 1.58 (2.99 to 0.16)
eGFR state 1 0 0
Univariate regression for ePrU states
Intercept 48.21 (47.37 to 49.05) 43.51 (42.63 to 44.38)
ePrU state 3 2.56 (4.25 to 0.86) 0.004 3.12 (4.69 to 1.56) 0.004
ePrU state 2 1.10 (1.99 to 0.22) 0.90 (1.74 to 0.06)
ePrU state 1 0 0
Multiple regression for eGFR and ePrU states
Intercept 47.70 (44.68 to 50.73) 49.21 (46.01 to 52.40)
Gender 2.47 (0.46 to 4.47) 0.020 2.78 (0.75 to 4.81) 0.010
Age at Dx for SLE 0.01 (0.07 to 0.05) 0.724 0.17 (0.24 to 0.10) <.001
Race/ethnicity 0.011 <.001
Other 0.94 (2.67 to 4.55) 0.04 (3.87 to 3.95)
African 0.41 (1.88 to 2.70) 1.48 (3.79 to 0.82)
Asian 2.76 (0.55 to 4.96) 3.53 (1.43 to 5.63)
Hispanic 3.42 (1.27 to 5.57) 4.95 (2.92 to 6.98)
Caucasian 0 0
SLEDAI w/o renal 0.19 (0.36 to 0.02) 0.036 0.34 (0.51 to 0.17) <.001
SDI w/o renal 0.911 <.001
54 0.78 (4.62 to 3.07) 4.90 (7.84 to 1.96)
3 0.32 (2.91 to 2.28) 3.97 (6.47 to 1.47)
2 0.66 (1.10 to 2.43) 3.00 (4.60 to 1.41)
1 0.24 (1.33 to 1.82) 1.59 (3.08 to 0.10)
0 0 0
Antimalarials 0.82 (1.97 to 0.33) 0.165 0.20 (0.82 to 1.22) 0.703
Immunosuppressants 0.19 (1.37 to 0.99) 0.750 0.19 (0.81 to 1.19) 0.713
Corticosteroids 0.72 (1.97 to 0.54) 0.266 1.97 (3.18 to 0.75) 0.002
Years since LN 0.30 (0.09 to 0.51) 0.006 0.33 (0.14 to 0.51) <.001
eGFR state 3 1.74 (4.75 to 1.27) 0.008 3.70 (6.58 to 0.83) 0.060
eGFR state 2 2.88 (4.55 to 1.21) 0.71 (2.31 to 0.89)
eGFR state 1 0 0
ePrU state 3 2.65 (4.54 to 0.76) 0.020 1.33 (3.02 to 0.36) 0.302
ePrU state 2 0.56 (1.50 to 0.38) 0.21 (1.01 to 0.60)
ePrU state 1 0 0
MCS: mental component summary score of SF-36; PCS: physical component summary score of SF-36; eGFR: estimated
glomerular filtration rate; ePrU: estimated proteinuria; Dx: diagnosis; w/o: without.
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for ESRD. In both studies, there was a strikingly higher
frequency of LN and ESRD in African Americans, who
were also the major racial/ethnic group. In the current
study, the cumulative incidence of ESRD (as defined by
stage 5 of the NKF classification of CKD) at 5 years was
3.3% and at 10 years following enrolment was 4.3% (as
defined in the SDI). Despite methodological differences in
study design, it is clear that ESRD and increased mortality
persist with current treatment modalities for LN.
The changes in the transition of ePrU states over 3 and
5 years indicate responsiveness to therapy for ePrU over
this time frame. Renal function, reflected by different
eGFR states and the CKD classification, did not change
appreciably. Small changes over time in the eGFR state
distribution cannot be excluded, due to the limited dur-
ation of follow-up, but these findings do suggest that
some patients with LN do not respond, in terms of a
marked improvement in renal function, to current treat-
ment modalities, either due to inefficacy, non-adherence
or toxicity necessitating discontinuation of medication.
Relatively few studies have examined HRQoL as a pri-
mary outcome in patients with LN. Three studies [4345]
have found that those undergoing treatment for severe LN
have clinically relevant changes in HRQoL up to 1 year
after the commencement of treatment, as quantified by
SF-36 scores. In the current study, HRQoL summary
scores were not lower for patients with nephritis at enrol-
ment when compared with patients who never developed
nephritis. However, patients with the most severe neph-
ritis, as indicated by higher eGFR and ePrU states, had
lower SF-36 subscale and summary scores. This associ-
ation with lower HRQoL was found in both cross-sectional
and longitudinal analyses, even after adjusting for multiple
potential confounders. Thus, stratification of patients by
severity of LN reveals significant associations with
HRQoL.
There are a number of limitations to the current study.
First treatment decisions were made on the basis of the
physician’s recommendation and patient preference
rather than study protocol. However, this reflects what
occurs in clinical practice and is a strength of the study.
Second, the SLICC network is based within academic
medical centres with a special interest in lupus, and our
data may not fully reflect community clinical practice.
Third, the frequency of renal biopsy was lower than ex-
pected. Recent guidelines [15, 16] encourage performing
renal biopsy in all SLE patients with possible renal dis-
ease. This permits confirmation of the diagnosis, charac-
terization of glomerular disease and a determination of
overall disease activity and renal scaring, all of which
inform treatment. Despite these advantages, previous ob-
servational cohort studies have indicated a highly variable
biopsy rate in 36.8% of 266 [46], 55% of 438 [47], 77% of
26 [48] and 96% of 127 [49] patients with a clinical diag-
nosis of LN. The reasons for not doing a renal biopsy on
patients in our cohort were multiple and included medical
contraindication, lack of access due to under-insurance in
a fee-for-service system, patient refusal and a low likeli-
hood of influencing the treatment plan, due to other major
organ involvement. Finally, our study was based upon a
disease inception cohort, and thus the disease duration
was shorter and age at enrolment younger than what is
seen in prevalent cohorts of lupus cases. As both factors
are associated with chronic kidney disease, further follow-
up is necessary to determine the long-term outcome of LN
in this cohort.
Despite these limitations, the study provides useful in-
formation on the frequency, characteristics and expect-
ations for outcome in patients with LN receiving current
standard of care. Most of the findings are applicable to
SLE patients in general and set the benchmark for plan-
ning future clinical trials of novel therapeutic agents and
protocols.
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